Marksans Pharma Recommends Final Dividend of ₹0.90 Per Share; AGM Scheduled for August 27, 2026
Marksans Pharma Limited has approved key aspects related to its upcoming Annual General Meeting (AGM) and announced a significant dividend recommendation for its shareholders. The company detailed the decision regarding the final dividend for the financial year ended March 31, 2026, and set the date for the members' meeting.The Board of Directors has recommended a final dividend amounting to ₹ 0.90 (90%) per equity share of face value ₹ 1/-. This recommendation is subject to formal approval by the Members at the upcoming AGM.
To determine eligibility for this final dividend, Marksans Pharma Limited fixed Thursday, August 20, 2026, as the Record Date. The company confirmed that if the final dividend receives approval at the AGM, it will be paid on or after Thursday, September 10, 2026, subject to any required tax deductions at source.
In addition to the dividend announcement, the Board of Directors announced details pertaining to the 34th Annual General Meeting (AGM). The company's members are scheduled to meet for the AGM on Thursday, August 27, 2026, at 11:00 a.m., which will be conducted through Video Conferencing (VC) or other Audio Visual Means (OAVM).
The Notice of the AGM, along with the Annual Report for FY 2026, will be made available in electronic mode to registered Members and on the company's website and the websites of the Stock Exchanges within prescribed timelines.
MARKSANS Stock Price Movement
As of 12:12 PM, shares of Marksans Pharma Limited are slipping by 1.72% in live trading, currently at ₹262.60 after shedding ₹4.60. The stock is seeing considerable movement as 682,486 shares trade in the market during this active session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.